May, 2023, Eutropics has entered an exploratory research agreement with Massachusetts General Brigham, a teaching hospital of Harvard Medical School, to support…

In October 2025, a publication in the International Journal of Molecular Sciences (doi:10.3390/ijms26209859) described Eutropics’ PRIMABS™ conformation‑specific antibody platform, which directly measures…

2019 – AASCO Annual Meeting (Chicago) Eutropics presented a poster titled, “Identifying Mcl-1 protein dependencies using dimerization-specific antibody biomarker for predicting response…

September, 2018, Eutropics Pharmaceuticals has been selected for a prestigious NIH/NCI SBIR Phase IIB Bridge Award providing 3 million dollars in non‑dilutive…

In June 2019, Eutropics Pharmaceuticals was awarded highly competitive funding from MassVentures’ SBIR Targeted Technologies (START) program to support the commercialization of…

September, 2024, Eutropics Pharmaceuticals is pleased to announce an extension of its long-standing research collaboration with the University of Texas MD Anderson…

December, 2024, in the United States, Eutropics and the Keck School of Medicine of the University of Southern California (USC) entered a…

April, 2025, Eutropics Protein/Protein interaction detectors platform is published in “Cancers” DOI: 10.3390 In this We describe a new diagnostics platform based…

October, 2025, PRIMABS recent article in the International Journal of Molecular Sciences (doi:10.3390/ijms26209859) describes Eutropics’ PRIMAB conformation‑specific antibody platform, which directly measures…